Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0000315066-15-002587.pdf
0000315066-15-002587.rtf
0000315066-15-002587.xls
EFFECT

EFFECT

 View HTML
9999999995-15-001054.pdf
9999999995-15-001054.rtf
9999999995-15-001054.xls
8-A12B

Registration of certain classes of securities 12(b) of the Securities Exchange Act

 View HTML
0001104659-15-030565.pdf
0001104659-15-030565.rtf
0001104659-15-030565.xls
CORRESP

CORRESP

 View HTML
0001104659-15-030559.pdf
0001104659-15-030559.rtf
0001104659-15-030559.xls
CORRESP

CORRESP

 View HTML
0001104659-15-030564.pdf
0001104659-15-030564.rtf
0001104659-15-030564.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003668.pdf
0001047469-15-003668.rtf
0001047469-15-003668.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003351.pdf
0001047469-15-003351.rtf
0001047469-15-003351.xls
CORRESP

CORRESP

 View HTML
0001104659-15-026544.pdf
0001104659-15-026544.rtf
0001104659-15-026544.xls
UPLOAD

UPLOAD

 View HTML
0000000000-15-020307.pdf
S-1

Registration statement for face-amount certificate companies

 View HTML
0001047469-15-002608.pdf
0001047469-15-002608.rtf
0001047469-15-002608.xls